路透8月6日 - Replimune公司周四表示,美国食品和药物管理局已批准其 REPL.O 药物用于治疗一种难以治愈的皮肤癌,这使这家生物技术公司在经历多年监管挫折后,终于拥有了首款上市产品。
路透8月6日 - Replimune公司周四表示,美国食品和药物管理局已批准其 REPL.O 药物用于治疗一种难以治愈的皮肤癌,这使这家生物技术公司在经历多年监管挫折后,终于拥有了首款上市产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.